Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction
- 1 March 2019
- journal article
- research article
- Published by Elsevier in Analytical Biochemistry
- Vol. 569, 53-58
Abstract
No abstract availableKeywords
Funding Information
- National Key Basic Research Program of China (2014CB744502)
- National Institute of General Medical Science (1RO1GM1058980)
- PREM (DMR-1523588)
- California State University
This publication has 40 references indexed in Scilit:
- A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitisJournal of Allergy and Clinical Immunology, 2012
- Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3Oncogene, 2011
- Structure-based Design of High Affinity Peptides Inhibiting the Interaction of p53 with MDM2 and MDMXJournal of Biological Chemistry, 2010
- Targeting the MDM2-p53 Interaction for Cancer TherapyClinical Cancer Research, 2008
- Structure-Based Design of Spiro-oxindoles as Potent, Specific Small-Molecule Inhibitors of the MDM2−p53 InteractionJournal of Medicinal Chemistry, 2006
- SW480, a p53 Double-mutant Cell Line Retains Proficiency for Some p53 FunctionsJournal of Molecular Biology, 2005
- MDM2 — master regulator of the p53 tumor suppressor proteinGene, 2000
- Regulation of p53 stability by Mdm2Nature, 1997
- Mdm2 promotes the rapid degradation of p53Nature, 1997
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976